Skip to content
etf.net

Launched · SEC filings

ARK Genomic Revolution ETF

ARKGCboeARKD

$48.33−3.07 (−5.97%)

At close: Nov 2, 2026, 4:00 PM ET

D33/ 100

Rank 15 of 17 in Biotech & Genomics

D33/100Rank 15 of 17inBiotech & Genomics
Intraday session: down, 79 prints from 51.40 to 48.33. Range 48.30 to 51.69. Use the arrow keys to read each point.49.0049.5050.0050.5051.0010 AM12 PM2 PM4 PM
Expense ratio
0.75%
Fund size
$2.22B
1Y total return
+65.1%
Yield · Last 12 months
0.00%
Holdings
35
Avg volume · 30D
4.31M sh
52W range
low $24.60high $58.83
Launched
Filings
SEC EDGAR

The ETF.net ARKG Grade

D

Score 33 out of 100

Category
Biotech & Genomics⁠
Rank
15 of 17
Six-pillar profile for ARKG. Scores out of 100: Cost 3, Risk 14, Mission 47, Tradability 83, Holdings 31, Durability 73. Strongest: Tradability (83). Weakest: Cost (3). Leans toward Tradability.

Score 33 of 100 falls in the D band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.

  • Cost

    The fund’s net expense ratio, ranked against its category.
    F3 out of 100
    Rank 16 of 17

  • Mission

    Whether the fund did what it promised, tested against its stated mandate.
    C47 out of 100
    Rank 8 of 9

  • Risk

    How the fund held up when markets fell: downside volatility, drawdowns and tail loss.
    F14 out of 100
    Rank 16 of 17

  • Tradability

    How easy the fund is to trade: daily volume, and how far its price strays from net asset value.
    A83 out of 100
    Rank 3 of 17

  • Holdings

    How concentrated the fund is, and how complete and current its disclosed holdings are.
    D31 out of 100
    Rank 16 of 17

  • Durability

    Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.
    A73 out of 100
    Rank 5 of 17

Our read on ARKG

ETF.net Research

In short

DMost genomics exposure comes prepackaged in an index. ARKG is the active version: ARK's team hand-picks a global slate of companies tied to the genomics revolution, and has since 2014.

Stated mandate

The Fund seeks long-term growth of capital through active investment, primarily in domestic and foreign equity securities of companies relevant to the genomics revolution theme.

Why people hold it

  • Active by design. ARK's managers choose the names instead of tracking a genomics index, so the portfolio can move as the science does.
  • Global mandate. The prospectus puts both domestic and foreign equities in bounds, so the hunt for genomics names isn't fenced in at the US border.
  • Live since 2014 and now a multibillion-dollar fund that trades actively, which makes getting in and out one of the easier parts of owning it.

Worth knowing

  • The stock picking costs you: 0.75% a year, above the category median, while index rivals like IBB (0.44%) and XBI (0.35%) charge less for broad biotech.
  • It sits at the more volatile end of its peer group. Concentrated bets on young science companies swing hard in both directions.
  • Long-term growth of capital is the stated job. Income isn't part of the mandate, so there's no dividend cushioning the ride.

ARKG Performance

Launched Oct 31, 2014

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

ARKG$16,511
SPY tracks large US stocks. It provides market context, rather than representing this fund’s strategy, asset class or investment benchmark.$11,199
Oct 31, 2025 to Oct 30, 2026. ARKG $16,511. SPY $11,199. Use the arrow keys to read each point.$10,000$15,000Oct 2025Apr 2026Oct 2026

Oct 31, 2025 – Oct 30, 2026

Returns run to the Oct 30, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for ARKG. Periods over one year show the average yearly return.
PeriodARKG
Year to date+77.4%
1 month−5.2%
3 months+33.3%
1 year+65.1%
3 yearsper year+30.7%
5 yearsper year−7.2%
10 yearsper year+12.8%

With distributions reinvested.

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual total returns for ARKG
YearReturn barARKG
2026 YTD+77.4%
2025+23.0%
2024−28.2%
2023+16.2%
2022−53.9%
2021−33.9%
2020+180.6%

ARKG in the news

ARKG Dividends

Adds up every distribution paid per share over the last 12 months, divided by the last completed close. Distributions are counted by ex-date. Data through Oct 30, 2026.
0.00%Last 12 months
Payout per share
NoneLast 12 months

No distributions in the last 12 months.

Distribution history

Payments through 2021

One bar per payment. 5 payments from 2017 to 2021. Dec 27, 2017 $0.33; Dec 27, 2018 $0.47; Dec 27, 2019 $1.05; Dec 29, 2020 $0.79; Dec 29, 2021 $0.38. Use the arrow keys to read each point.20172018201920202021
Ex-datePay dateAmount per share
Dec 29, 2021Dec 31, 2021$0.38
Dec 29, 2020Dec 31, 2020$0.79
Dec 27, 2019Dec 31, 2019$1.05
Dec 27, 2018Dec 31, 2018$0.47
Dec 27, 2017Dec 29, 2017$0.33

$10,000 in ARKG 10 years ago paid $1,904 in dividends.

ARKG Risk

Risk pillarF14 out of 100Rank 16 of 17 in Biotech & Genomics
How much the fund’s monthly returns vary, scaled to a year.
40.8%
Annualised · 36 months to Oct 2026
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
0.75
vs 3-month T-bills · to Oct 2026
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
−76.5%
Trough Apr 2025
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
2.38
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

FMP measures it over up to five years of monthly returns.

ARKG Cost

Compare ARKG and IBBQ

Overpaying vs IBBQ, cheapest in Biotech & Genomics

$10,530

On $10,000 over 30 years. 7% growth a year before fees, expense ratio only.

  • ARKG 0.75%

    $14,482

  • IBBQ 0.19% Cheapest

    $3,952

$10,000
30 years

Cost over time

  • ARKG 0.75%
  • IBBQ 0.19%
  • Overpaying
One line per fund, from year 0 to year 30. Use the arrow keys to read each point.$0$5K$10K$15K051015202530ARKG $14,482IBBQ $3,952

Year by year

YearARKGIBBQOverpaying
10$1,336$347$989
20$5,078$1,351$3,727
30$14,482$3,952$10,530

Other funds in Biotech & Genomics

See others